#Denmark #Lundbeck #bexicaserin #Valby #DEEs

Lundbeck's Recent Findings on Bexicaserin in Childhood-Onset Epilepsies

At the 2025 American Epilepsy Society (AES) Congress held in Atlanta, major advancements regarding the investigational compound bexicaserin (LP352) were announced by H. Lundbeck A/S. These findings encompass long-term data demonstrating that patients with Developmental and Epileptic Encephalopathies (DEEs) have benefited significantly from the treatment.

Understanding DEEs

DEEs are a spectrum of rare and severe epilepsy syndromes that commonly emerge in childhood and exhibit complex characteristics. These conditions often involve drug-resistant seizures and significant developmental challenges, leaving patients heavily reliant on the support of caregivers. Given that conventional anti-seizure medications frequently fail to provide adequate relief, the pressing need for innovative therapeutic options remains critical.

Promising Results from Long-Term Data

The newly presented long-term data at AES indicate that patients who initiated treatment with bexicaserin continue to experience meaningful reductions in seizure frequency, with results tracked for as long as two years. Specifically, during this follow-up period, patients reported a median reduction in countable motor seizures of approximately 60.2% at 18 months and 53.7% at 24 months when compared to their baseline at the start of the PACIFIC trial.

Durable Effects across DEE Variants

Interestingly, these seizure reduction rates held consistent across various DEE types, including Dravet Syndrome and Lennox-Gastaut Syndrome, showcasing bexicaserin’s potential as a broad-spectrum therapeutic option for diverse DEEs. As families navigate the ongoing emotional and financial burdens associated with managing such debilitating conditions, the long-term efficacy of bexicaserin brings a new ray of hope.

Safety Profile

Another crucial aspect of the findings highlighted at the AES Congress was the favorable safety and tolerability profile associated with bexicaserin. Notably, no new safety concerns emerged during the two-year treatment phase, reinforcing its viability as a first-in-class therapy for DEEs. Early data suggests that bexicaserin has a minimal risk of drug-drug interactions, promising a viable alternative for patients needing enhanced seizure management.

Future Implications

As the need for effective treatments for DEEs grows increasingly urgent, Lundbeck’s research and dedication toward addressing these complex neurological challenges reflect their commitment to advancing healthcare solutions. “We are increasingly hopeful that bexicaserin can address this need,” commented Johan Luthman, EVP and Head of Research and Development at Lundbeck. This encapsulates the company's vision to deliver transformative medications where no options currently exist.

In summary, the presentation of positive long-term data for bexicaserin signals a significant milestone in the search for effective treatments for childhood-onset epilepsies. As clinical trials continue, the possibility of introducing a new standard in care for families affected by DEEs seems promising, encouraging further exploration and research into this groundbreaking therapy.